A new device classification
The U.S. Food and Drug Administration granted De Novo authorization for the OTTAVA Robotic Surgical System on July 21, 2026, and Johnson & Johnson announced the decision the next day. The FDA database identifies the new classification as an integrated operating table-electromechanical surgical system, with De Novo number DEN250068.
De Novo review is used for a novel, low-to-moderate-risk device when there is no legally marketed predicate suitable for the standard 510(k) pathway. A granted decision creates a classification and regulatory controls that later devices may be able to use as a predicate. It is a marketing authorization for specified uses, not a general endorsement of every possible procedure or a finding that the system improves every clinical outcome.
OTTAVA was authorized for several upper-abdominal general-surgery procedures. Johnson & Johnson lists gastric bypass, gastrectomy, gallbladder removal, splenectomy, gastric sleeve, small-bowel resection, appendectomy, adhesion removal, fundoplication and hiatal-hernia repair. The company planned a selective U.S. commercial launch while continuing a trial in inguinal-hernia procedures.
The arms move with the operating table
Four robotic arms are integrated into the surgical table rather than mounted on a separate boom or several independent bedside carts. Software coordinates predefined setup poses, and a feature called twin motion moves the table and arms together when the patient is repositioned. The design is intended to preserve access to different parts of the abdomen with fewer manual changes.
Johnson & Johnson says the system occupies 30 to 50 percent less floor space than traditional boom- or cart-mounted multi-port systems, based on its evaluation of products available in September 2025. That is a manufacturer-supported footprint comparison. Whether a hospital gains usable time or capacity will depend on its room, staff workflow, procedure mix and training.
The instrument set includes a combined needle driver designed to reduce accidental suture cutting and curved monopolar scissors. A connected digital platform supports training, media and surgical data. These features address the full operating-room workflow, where setup, instrument exchange and team movement can matter as much as the arm mechanism.
Robotic assistance is not autonomous surgery
The FDA explains that marketed robotically assisted surgical devices are controlled directly by a trained surgeon. OTTAVA's automated setup and coordinated table motion do not make it an autonomous surgeon. The physician remains responsible for operating the instruments and making clinical decisions.
This distinction separates OTTAVA from 2025 research systems that learned to complete an experimental surgical phase without continuous human control. The two developments address different problems: one is an authorized teleoperated clinical platform and the other is preclinical autonomy research.
What authorization establishes—and what comes next
The FDA decision means the agency found reasonable assurance of safety and effectiveness for the intended uses under the applicable controls. It does not establish superiority over open, laparoscopic or other robot-assisted approaches. Comparative outcomes, learning curves, reliability and cost will emerge through clinical use and postmarket evidence.
Training remains central. The FDA advises hospitals to verify that surgeons and staff are properly trained and credentialed for each device model. It also monitors malfunction, injury and death reports, while noting that reports can be duplicated, incomplete or unable to prove causation.
OTTAVA's 2026 authorization broadens the U.S. surgical-robot market and validates a table-integrated architecture as a regulated product category. The consequential next phase is less visual than a product launch: controlled adoption, transparent outcomes and surveillance across many teams and patients. Those data will determine whether the smaller footprint and coordinated motion translate into safer, more efficient or more accessible care.